Karyopharm Therapeutics
KPTIAlgoritmens signaler
- ›Pris under både MA50 och MA200 (svag trend)
- ›Hög volatilitet (278% årlig)
- ›Ökad handelsvolym (+274%)
- ›-83% från 52v-toppen
- ›Svagt 3m-momentum (-76.9%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsKPTI Stock Crashes As Trial Failure Triggers Legal Scrutiny - StocksToTrade
12 h sedanKPTI Stock Crashes As Trial Failure Triggers Legal Scrutiny StocksToTrade
StocksToTradeKPTI Stock Collapses As Karyopharm’s Key Cancer Trial Fails And Legal Risks Mount - timothysykes.com
1 d sedanKPTI Stock Collapses As Karyopharm’s Key Cancer Trial Fails And Legal Risks Mount timothysykes.com
timothysykes.comKPTI|Karyopharm Therapeutics Inc|Price:1.920|Chg%:-5.090 - TradingKey
2 d sedanKPTI|Karyopharm Therapeutics Inc|Price:1.920|Chg%:-5.090 TradingKey
TradingKeyKaryopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move - TradingView
2 d sedanKaryopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move TradingView
TradingViewKaryopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer - Seeking Alpha
3 d sedanKaryopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Seeking AlphaKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
3 d sedanKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway PR Newswire NEWTON, Mass., July 30, 2026 – Company Plans to Submit sNDA in August
Karyopharm TherapeuticsPR NewswireIf approved, Karyopharm's combination could be the first for myelofibrosis - Stock Titan
3 d sedanIf approved, Karyopharm's combination could be the first for myelofibrosis Stock Titan
Stock TitanKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
3 d sedanKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PR Newswire NEWTON, Mass., July 30, 2026 – The Trial Did Not Meet the Primary Endpoint of Progression-Free
Karyopharm TherapeuticsPR NewswireKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., July 1, 2026 NEWTON, Mass. , July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics I
Karyopharm TherapeuticsPR NewswireKaryopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Yahoo Finance
2026-06-25Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update Yahoo Finance
Yahoo FinanceKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
2026-06-03Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PR Newswire NEWTON, Mass., June 3, 2026 NEWTON, Mass. , June 3, 2026 /PRNewswire/ -- Karyopharm
Karyopharm TherapeuticsPR NewswireKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
2026-06-02Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PR Newswire NEWTON, Mass., June 2, 2026 – New Data will Hig
Karyopharm TherapeuticsPR NewswireKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
2026-06-02Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of C
Karyopharm TherapeuticsPR NewswireKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., June 1, 2026 NEWTON, Mass. , June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics In
Karyopharm TherapeuticsPR NewswireKaryopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
2026-06-01Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation PR Newswire NEWTON, Mass., June 1, 2026 – Eve
Karyopharm TherapeuticsPR NewswireKaryopharm to Participate at the 2026 Jefferies Global Healthcare Conference
2026-05-28Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass., May 28, 2026 NEWTON, Mass. , May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasda
Karyopharm TherapeuticsPR Newswire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.